source
- European pharma CEOs warn of biotech decline as R&D share drops to 31% and call for faster trials and stronger IP protectionNine leading European pharma board chairs issued an open letter warning that Europe is losing its biotech edge. They note that Europe's share of global pharma R&D fell from 43% in 1990 to 31% toda…
- FDA advisory panel backs Grail's Galleri multi-cancer blood test, citing benefits outweigh risksThe Food and Drug Administration’s advisory committee voted to endorse Galleri, a blood test from Grail that screens for multiple cancers, saying the benefits outweigh the risks. The panel’s vote…